title: [Lidocaine as an immunomodulator in a toxic liver lesion].
abstract: D-galactosamine (DGA) increases the malonic dialdehyde (MDA) content in the erythrocytes, reduces the ATP content, and induces the appearance of immunosuppressive properties in the red cells. Administration of lidocaine attenuates or completely removes these effects of DGA in poisoned animals. Extracorporeal treatment of the erythrocytes of intact rats with blood serum of DGA-poisoned reduces the ATP content and induces the appearance of immunosuppressive properties in the erythrocytes. Blood serum of DGA-poisoned rats which had been given lidocaine does not cause such effects.
authors.forename: B S
authors.initials: BS
authors.lastname: Uteshev
authors.forename: L G
authors.initials: LG
authors.lastname: Prokopenko
authors.forename: E N
authors.initials: EN
authors.lastname: Konoplia
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005688:Galactosamine / Q000506:poisoning; D007114:Immunization; D008012:Lidocaine / Q000627:therapeutic use*; D011041:Poisoning / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D005688:Galactosamine; D008012:Lidocaine